



---

**Date:** May 4, 2020  
**To:** All Calgary Zone Physicians and Healthcare Providers; and APL Managers and Supervisors, MLT II/III, LIC, Accessioning, Clinical Biochemists  
**From:** Clinical Biochemistry, South Sector, Alberta Precision Laboratories (APL)  
**Re:** Discontinuation of Serum Lithium measurement in High River and Plasma Digoxin and Phenytoin measurement in Strathmore and High River

---

**PLEASE POST OR DISTRIBUTE AS WIDELY AS APPROPRIATE**

---

**Key Message:**

- Effective **May 1, 2020**, serum lithium will no longer be measured at High River Hospital, and plasma digoxin and phenytoin will no longer be measured at Strathmore District Health Services and High River Hospital.
- Referral Patterns are:

<u>Specimen source</u>	<u>Analyte</u>	<u>Performing Lab</u>
High River	Lithium	Foothills Medical Center (FMC)
	Digoxin & Phenytoin	South Health Campus (SHC)
Strathmore	Digoxin & Phenytoin	Peter Lougheed Center (PLC)
- Anticipated turnaround time for Stat requests is 2 hours.

**Why this is Important:**

- Requests for digoxin, phenytoin and lithium assays are not frequent enough to justify maintaining costly quality control analysis and external proficiency testing.

**Action Required:**

- No change in ordering is required. Samples will be redirected automatically by the Chemistry laboratory.

**Inquiries and feedback may be directed to:**

- Jessica Gifford, PhD, Clinical Biochemist, 403-770-3779, [Jessica.Gifford@albertaprecisionlabs.ca](mailto:Jessica.Gifford@albertaprecisionlabs.ca)
- Amid Abdullah, MD, General Pathologist, 403-770-3670, [Amid.Abdullah@albertaprecisionlabs.ca](mailto:Amid.Abdullah@albertaprecisionlabs.ca)

**This bulletin has been reviewed and approved by:**

Hossein Sadrzadeh, PhD, FAACC, Clinical Section Chief, Clinical Biochemistry, South Sector  
Leland Baskin, MD, FCAP, FAACC, Associate Medical Director, South Sector